Overview

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer